A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data

Article English OPEN
Wang, Han I; Roman, Eve; Crouch, Simon; Aas, Eline; Burton, Cathy; Patmore, Russell; Smith, Alexandra Gwen;

Objectives To use real-world data to develop a flexible generic decision model to predict cost, life expectancy, and quality-adjusted life-years (QALYs) for follicular lymphoma (FL) in the general patient population. Methods All patients newly diagnosed with FL in the U... View more
  • References (43)
    43 references, page 1 of 5

    Supplemental material accompanying this article can be found in the online version as a hyperlink at https://doi.org/10.1016/j.jval.

    [1] Smith A, Roman E, Howell D, et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 2010;148:739-53.

    [2] Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684-92.

    [3] Haematological Malignancy Research Network. HMRN 2018. https:// www.hmrn.org/statistics/incidence. [Accessed January 10, 2018].

    [4] Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-andwait approach in patients with advanced-stage, asymptomatic, nonbulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014;15:424-35.

    [5] van Agthoven M, Kramer MHH, Sonneveld P, et al. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. Haematologica 2005;90:1422-32.

    [6] Beveridge R, Satram-Hoang S, Sail K, et al. Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma 2011;52:2117-23.

    [7] Wake B, Hyde C, Byran S, et al. Rituximab as third-line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-85.

    [8] Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008;8:166-70.

    [9] Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:227-36.

  • Metrics
Share - Bookmark